With price controls continuing to crimp margins, Sanofi India expects a muted growth in the domestic market in 2017 and therefore the company will be focusing on volumes as well as exports.
“We expect to continue to face annualised negative impact of price cuts imposed in 2016. Due to this reason, growth of domestic business will be muted in value terms in 2017.
Therefore our focus will be to drive the volume growth as well as exports, which is likely to grow steadily,” Sanofi India said in its annual report for 2016.
Managing Director Shailesh Ayyangar said the focus will be to increase the domestic volume growth on one side and drive exports on the other, as the latter looks more promising.
To shore up exports, he said Sanofi is in the process of unveiling a strategic project to boost its competitiveness and productivity through operational improvement as part of a specially designed programme named ‘Fit for Future’ at both its manufacturing sites.
It can be noted that the number of medicines falling under market-based price controls has gone up to nearly 650 formulations after the March 2016 list, which constitutes nearly 20 per cent of the total market.
Last year, the government had amended the Drug Price Control Order (DPCO) following which the National Pharmaceutical Pricing Authority (NPPA) fixed the ceiling prices of medicines and pharma companies reduced the prices of those medicines in compliance with the new norms. This has affected the profitability of the sector.
The domestic pharma industry grew 11 per cent in 2016.
The demand for pharma products has been buoyant owing to the growing disease burden and affordable prices of a large number of essential drugs.
Ayyangar said its drugs in the price control include Amaryl, Brodactum, Cardace, Cetapin, Frisium and Taxotere in addition to Arava, Avil, Clexane, Lasix and Insuman.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.